Table 3

Structured assessment clinic.

(n=200)ICU (n=77)Non-ICU (n=123)ICU versus non-ICU
MRC (median ±IQR)2±13±12±1p=0.026
Delta MRC (median ±IQR)1±11±11±1p=0.04
 6MWT (n=170)
 Distance (m)342±169342±305429±306p=0.181
 % predicted (median ±IQR)70.4±42.063.9±54.570.4±40.8
 Resting SpO2 (%) (median ±IQR)96.0±2.096.0±2.096.0±2.3p=0.996
 Nadir SpO2 (%) (median ±IQR)94±494±494±4p=0.858
 >4% desaturation341222p=0.693
 Max HR (median ±IQR)111±17108±20115±16p=0.310
D-dimer (0.00–0.55 mg/L) (median ±IQR)0.48±1.000.99±1.000.46±1.00p=0.126
Ferritin (30–400 μg/L) (median ±IQR)164±234186±234145±216p=0.340
Lymphocyte (1.2–3.5×109/L) (median ±IQR)1.9±1.02.1±1.01.8±0.9p=0.001
C reactive protein (0–4 mg/L) (median ±IQR)6.2±2.06.5±3.02.0±3.0p=0.597
Questionnaires
 PHQ9 (median ±IQR)3.0±11.07.0±128.0±11.3p=0.621
 PHQ9 ≥10 (%)32 (16%)11 (14.3)21 (17.1)
 GAD7 (median ±IQR)4.0±9.58.0±11.03.0±6.0p=0. 168
 GAD7 ≥10 (%)22 (11%)11 (14.3)11 (8.9)
 STOPBANG (median ±IQR)3.0±2.03.0±1.02.5±1.8p=0.682
 STOPBANG ≥4 (%)36 (18.0)12 (15.6)22 (17.0)
RR (95% CI)
Cardiorespiratory cause of breathlessness81 (40.5)43 (55.8)38 (30.9)2.8 (1.5 to 5.1)
 Persistent parenchymal change (%)64 (32.0)35 (45.5)29 (23.6)2.7 (1.4 to 4.9)
 PE (%)4 (2.0)1 (1.3)3 (2.4)0.5 (0.1 to 5.1)
 Other respiratory (%)5 (2.5)4 (5.1)1 (0.8)6.7 (0.7 to 60.1)
 Cardiac (%)8 (4.0)2 (2.6)6 (4.9)0.7 (0.2 to 2.6)
  • GAD7, generalised anxiety disorder questionnaire 7; HR, heart rate; ICU, intensive care unit; 6MWT, 6 min walk test; PHQ9, patient health questionnaire 9; RR, risk ratio; SpO2, oxygen saturations; STOPBANG, snoring, tiredness, observed apnoeas, high blood pressure, BMI, age, neck circumference and male gender questionnaire.